UNSPSC 51373201: Dioxaphetyl

This classification denotes an opioid receptor agonist and opioid and analgesic agent with the molecular formula C22H27NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier G751H98FY4, chemically known as 4-morpholinebutyric acid, alpha,alpha-diphenyl-, ethyl ester but generally known as dioxaphetyl butyrate, which bears US NIH Compound Identifier 48194. European Medicines Agency schedules Dioxaphetyl in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07202MIG.

The term DIOXAPHETYL is an International Non-Proprietary Name. SMILES: CCOC(=O)C(CCN1CCOCC1)(C2=CC=CC=C2)C3=CC=CC=C3.

UNSPSC 51373201 Dioxaphetyl is a Commodity code that state and local governments are using to procure naloxone, drug deactivation systems, generic pharmaceuticals, and over-the-counter products through competitive bidding and cooperative purchasing vehicles. The solicitations show county health departments, state health and human services agencies, and multistate cooperative purchasing alliances buying pharmaceutical inventory—both specialized emergency-response products like naloxone and broad-based generic medication catalogs distributed through wholesaler networks. Issuing bodies span county health systems (Seminole County, Florida), state health agencies (Texas Health and Human Services Commission), and multistate cooperative purchasing organizations (Minnesota Multistate Cooperative Purchasing Alliance, serving participating state and local governments including Oregon). The mix reflects both direct procurement by individual counties and centralized statewide or regional contracting to achieve volume and pricing leverage across multiple jurisdictions.

Recent opportunities include Seminole County's IFB60459723LAS (posted June 30, 2026, due July 26, 2023) seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida; the Texas Health and Human Services Commission's RFI HHS0017013 (posted April 3, 2026) to gather vendor capabilities for direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager channels; and Minnesota's MMCAP RFP S1070000015802 (posted January 20, 2026, due March 26, 2026) to establish multiple contracts for generic multi-source pharmaceuticals and OTC products distributed through authorized wholesalers (AmerisourceBergen, Cardinal Health, Morris & Dickson) to participating state and local facilities, with awards effective July 1, 2026. Activity spans Florida, Texas, and the Upper Midwest, with MMCAP representing a particularly active cooperative purchasing vehicle for state and local pharmaceutical procurement across multiple jurisdictions.